Malignant Pleural Effusions

Hott, J.

doi:10.1055/s-2007-1009844

Cited by 3 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer is the leading cause of malignant pleural effusion (MPE) [1][2][3][4][5]. Approximately 15% of lung cancer patients have pleural effusion at the time of initial diagnosis and 50% develop pleural effusion later in their causes [3,5,6]. Patients with pleural effusion have life short expectancy and are difficult to manage clinically [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…Approximately 15% of lung cancer patients have pleural effusion at the time of initial diagnosis and 50% develop pleural effusion later in their causes [3,5,6]. Patients with pleural effusion have life short expectancy and are difficult to manage clinically [3,4]. A more definitive management strategy is often undertaken with several approaches available to physician or surgeon.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ipsilateral Pleura Radiotherapy Combined Intrapleural with Intravenous Chemotherapy for Patients with NSCLC Presenting Malignant Pleural Effusion

Uddin

2019

CTOIJ

View full text Add to dashboard Cite

Purpose: Patients with non-small cell lung cancer (NSCLC) and malignant pleural effusion (MPE) are difficult to manage clinically. In this study, we designed a protocol of combined ipsilateral pleura radiotherapy with intrapleural(i.p.) and intravenous(i.v.) chemotherapy to enhance local as well as systemic control of the disease.Method: From January 2006 to January 2011, 31 patients with NSCLC and MPE were eligible for the study. After adequate drainage, patients received chemotherapy (cisplatin 60mg/m 2 i.p. on day 1, paclitaxel 125mg/m 2 and cisplatin 75mg/m 2 on days 3 and 31 i.v.), and after first cycle chemotherapy followed by forward IMRT. Radiation targets included primary tumor, mediastinal, lymphatic drainage area, the ipsilateral pleura and 1/2 pleural effusion. The radiation dose is 190cGy / fraction. After 6080cGy/32 fractions delivered, residues tumours were given with boost irradiation 570～950 cGy /3～5 fractions.Result: Overall response of pleural effusion was 90.3% with 38.7% complete remission, 51.6% with partial remission, 6.5% stable disease, and 3.2 % progressive disease. The median failure-free and overall survival was 13 and18 months, respectively. 1-and 2-years overall survival was 77.3% and 19.9%. Grade 1, 2, 3 and 4 of lung and esophagus acute radiation-induced toxicity was 58.1%,19.4%,3.2% and 0% and 48.4%9.7%, 3.2% and 0%. The rate of grade 1, 2, 3 and 4 with hematologic toxicity was 38.5%, 23.1%, 3.8%, and 0%. Conclusion:Ipsilateral pleura radiotherapy combined with intrapleural and intravenous Chemotherapy for patients with NSCLC presenting malignant pleural effusion is feasible, effective, and provides an alternative treatment modality for them.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Ipsilateral Pleura Radiotherapy Combined Intrapleural with Intravenous Chemotherapy for Patients with NSCLC Presenting Malignant Pleural Effusion

Uddin

2019

CTOIJ

View full text Add to dashboard Cite

show abstract

Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions

Perng

Chen

et al. 1998

Respiratory Medicine

View full text Add to dashboard Cite

A phase II clinical trial of intrapleural paclitaxel injection for malignant effusions of non-small-cell lung cancer (NSCLC) was conducted in order to evaluate the efficacy and toxicity profile of paclitaxel pleurodesis in patients with malignant effusions. From February to May of 1996, 15 NSCLC patients with malignant pleural effusions were enrolled on study. After adequate drainage and assurance of lung re-expansion, paclitaxel 125 mg m-2 diluted in normal saline was infused through a preinserted pig-tail catheter which was removed 2 h later. Chest radiography and sonography were scheduled 4 days later; depending on whether there remained a significant amount of pleural effusion, further drainage by needle thoracentesis or by a pig-tail catheter was performed. All patients were assessable for toxicity. Ipsilateral chest and/or shoulder pain, fever, facial flushing and nausea were the most frequent side-effects. Grade 4 neutropenia, grade 3 anaemia, and grade 3 renal impairment occurred in one patient each. Fourteen patients were evaluable for response at the end of the fourth week. Overall response rate of pleural effusion in evaluable patients was 92.9%, with a complete response rate of 28.6%. There was one out of 14 evaluable patients whose measurable tumour lesion decreased by more than 50% (partial response). No disease progression was noted among evaluable patients at the end of the fourth week. It is concluded that paclitaxel is a useful agent for the treatment of malignant pleural effusions. Because of its relatively low systemic toxicity, intrapleural paclitaxel injection in combination with systemic chemotherapy or radiotherapy can be considered in treating NSCLC patients with malignant pleural effusions.

show abstract

Management of Malignant Pleural Effusions

Nemcek¹

1998

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

Malignant Pleural Effusions

Cited by 3 publications

References 53 publications

Ipsilateral Pleura Radiotherapy Combined Intrapleural with Intravenous Chemotherapy for Patients with NSCLC Presenting Malignant Pleural Effusion

Ipsilateral Pleura Radiotherapy Combined Intrapleural with Intravenous Chemotherapy for Patients with NSCLC Presenting Malignant Pleural Effusion

Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions

Management of Malignant Pleural Effusions

Contact Info

Product

Resources

About